Biliary Tract Cancer
Conditions
Interventions
Observation group:None
Sponsors
Jiangsu Province Hospital of Chinese Medicine
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients with pathologically confirmed unresectable or metastatic BTC 2. Aged 18–75 years, regardless of gender 3. ECOG score of 0–2 4. Expected survival time >= 12 weeks 5. At least one measurable lesion (RECIST 1.1 criteria) 6. Received liposomal irinotecan (II) during second-/third-line treatment for BTC 7. Complete records of liposomal irinotecan (II) administration available 8. Fully informed about the study, voluntarily participate, and sign the informed consent form
Exclusion criteria
Exclusion criteria: 1. Diagnosed with other malignant tumors within the past 5 years 2. Presence of uncontrolled distant metastases, such as brain metastases 3. History of liver transplantation 4. Liver metastases occupying 50% or more of the total liver volume 5. Incomplete case data affecting efficacy and safety evaluation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Disease control rate;1-year S.R.; | — |
Countries
China
Contacts
Public ContactQian Jun / Cheng Ying
Jiangsu Province Hospital of Chinese Medicine
Outcome results
None listed